Skip to main content
Fig. 8 | Antimicrobial Resistance & Infection Control

Fig. 8

From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Fig. 8

Probabilistic sensitivity analysis for CAZ-AVI sequence vs. meropenem sequence (on cost-effectiveness plane). Abbreviations: CAZ-AVI ceftazidime-avibactam, QALY quality-adjusted life year, WTP willingness-to-pay.

CAZ-AVI sequence: CAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem.

Meropenem sequence: Meropenem, followed by colistin + tigecycline + high-dose meropenem.

Notes: Each dot represents cost-effectiveness outcome from each iteration. The threshold lines represent cost-effectiveness thresholds (€ 30,000 or € 40,000 per QALY), the maximum amount society is willing to pay for a QALY gain. In cases that fall to the right and below this line, the CAZ-AVI sequence is cost effective compared to the meropenem sequence. In cases that fall to left and above this line, the CAZ-AVI sequence is not cost effective compared to the meropenem sequence

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us